TY - JOUR
T1 - Effectiveness of therapies for heroin addiction in retaining patients in treatment
T2 - Results from the vedette study
AU - VEdeTTE STUDY GROUP
AU - Salamina, Giuseppe
AU - Diecidue, Roberto
AU - Vigna-Taglianti, Federica
AU - Jarre, Paolo
AU - Schifano, Patrizia
AU - Bargagli, Anna Maria
AU - Davoli, Marina
AU - Amato, Laura
AU - Perucci, Carlo Alberto
AU - Faggiano, Fabrizio
AU - Burroni, P.
AU - Nicoletti, G.
AU - Perucci, CA
AU - Renga, G.
AU - Baldassarre, C.
AU - Maria Bargagli, A.
AU - Belleudi, V.
AU - Boccalon, R.
AU - Carlomagno, L.
AU - Carobene, A.
AU - Casella, P.
AU - Cipriani, F.
AU - Conforti, R.
AU - Cuomo, GL
AU - Della Bona, S.
AU - Diecidue, R.
AU - Faggiano, F.
AU - Filippazzo, G.
AU - Grande, B.
AU - Guelfi, GP
AU - Lovaste, R.
AU - Magliocchetti, N.
AU - Martini, C.
AU - Mathis, F.
AU - Montina, L.
AU - Pani, PP
AU - Pavarin, RM
AU - Piras, G.
AU - Salamina, G.
AU - Sbrana, R.
AU - Scarmozzino, A.
AU - Schifano, P.
AU - Scondotto, S.
AU - Sgarzini, P.
AU - Sorio, C.
AU - Triassi, M.
AU - Versino, E.
AU - Vigna-Taglianti, F.
AU - Villani, G.
AU - Baraldi, F.
N1 - Funding Information:
Treatment is effective in reducing heroin use and clinical and social problems among heroin addicts. The effectiveness is related to the duration of treatment. “VEdeTTE” is an Italian longitudinal study funded by the Ministry of Health to evaluate the effectiveness of treatments provided by the National Health Services. The study involved 115
Funding Information:
We thank the staff of NHS treatment centers throughout Italy whose active support was essential for the VEdeTTE study. We especially thank Federica Mathis for acquisition of data, GianLuca Cuomo for data management, and Matthew Hickman for the comments on the first draft. This study was supported by a research grant from the National Fund for Drug Addiction provided by the Ministry of Health and by the Regional Fund for Drug Addiction of Piedmont Region.
PY - 2010/7/1
Y1 - 2010/7/1
N2 - Treatment is effective in reducing heroin use and clinical and social problems among heroin addicts. The effectiveness is related to the duration of treatment. "VEdeTTE" is an Italian longitudinal study funded by the Ministry of Health to evaluate the effectiveness of treatments provided by the National Health Services. The study involved 115 drug treatment centers and 10,454 heroin users. Clinical and personal information were collected at intake through a structured interview. Treatments were recorded using a standardized form. Survival analysis and Cox Proportional Hazard model were used to evaluate treatment retention. Five thousand four hundred and fifty-seven patients who started a treatment in the 18 months of the study were included in the analysis: 43.2% received methadone maintenance therapy (MMT), 10.5 therapeutic community, and 46.3% abstinence-oriented therapy (AOT). The likelihood of remaining in treatment was 0.5 at 179 days. The median daily dose of methadone was 37 mg. Psychotherapy was provided in 7.6% of patients receiving methadone and 4.9% of those in therapeutic community. Type of therapy was the strongest predictor of retention, with AOT showing the lowest retention. In MMT patients, retention improved according to dose. Living alone, psychiatric comorbidity and cocaine use increased the risk of dropout. Psychotherapy associated halved the risk of dropout.
AB - Treatment is effective in reducing heroin use and clinical and social problems among heroin addicts. The effectiveness is related to the duration of treatment. "VEdeTTE" is an Italian longitudinal study funded by the Ministry of Health to evaluate the effectiveness of treatments provided by the National Health Services. The study involved 115 drug treatment centers and 10,454 heroin users. Clinical and personal information were collected at intake through a structured interview. Treatments were recorded using a standardized form. Survival analysis and Cox Proportional Hazard model were used to evaluate treatment retention. Five thousand four hundred and fifty-seven patients who started a treatment in the 18 months of the study were included in the analysis: 43.2% received methadone maintenance therapy (MMT), 10.5 therapeutic community, and 46.3% abstinence-oriented therapy (AOT). The likelihood of remaining in treatment was 0.5 at 179 days. The median daily dose of methadone was 37 mg. Psychotherapy was provided in 7.6% of patients receiving methadone and 4.9% of those in therapeutic community. Type of therapy was the strongest predictor of retention, with AOT showing the lowest retention. In MMT patients, retention improved according to dose. Living alone, psychiatric comorbidity and cocaine use increased the risk of dropout. Psychotherapy associated halved the risk of dropout.
KW - Heroin addiction
KW - Methadone dose
KW - Methadone maintenance
KW - Psychotherapy
KW - Therapeutic community
KW - Treatment retention
UR - https://www.scopus.com/pages/publications/77954453628
U2 - 10.3109/10826081003791932
DO - 10.3109/10826081003791932
M3 - Article
SN - 1082-6084
VL - 45
SP - 2076
EP - 2092
JO - Substance Use and Misuse
JF - Substance Use and Misuse
IS - 12
ER -